Cat. No. 2671
Chemical Name: (11β,16α)-16,17-[Butylidenebis(oxy)]-
Biological ActivitySynthetic anti-inflammatory glucocorticoid that displays chemopreventive activity. Prevents formation of lung adenomas and adenocarcinomas in mice following inhalation or oral administration. Reverses DNA hypomethylation and modulates expression of cancer related genes.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Wattenberg et al (2007) Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 57 5489.
Pereira et al (2006) Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. Int.J.Cancer 120 1150.
Spencer et al (1995) Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50 854. PMID: 8586030.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Budesonide from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Budesonide, supplier, Synthetic, glucocorticoid, anti-inflammatory, chemopreventive, Receptors, Tocris Bioscience, Glucocorticoid Receptor products
Find multiple products by catalog number
New Products in this Area
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonistIP7e
Potent Nurr1 activatorBexarotene
Potent and selective RXR agonistGSK 2033
Potent LXR antagonist27-Hydroxycholesterol
LXR agonist; also ER partial agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.